The ERICCIN trial is a single-centre , randomised double-blinded placebo-controlled trial which plans to recruit 362 patients who are at risk of CIN , defined by pre-existent renal impairment ( estimated glomerular filtration rate < 60 ml/min/1 .73 m2 ) , over a period of 2 years .